During the corresponding time, Emergent Biosolutions Inc recorded a revenue increase by 66.29 % year on year, sequentially revenue grew by 50.1 %. While revenue at the Emergent Biosolutions Inc 's corporate clients
Emergent Biosolutions Inc's Comment on Sales, Marketing and Customers
The Company operates in markets addressing global public health threats such as smallpox, mpox, anthrax, Ebola, and opioid overdose emergencies. Its business is organized into four product and service categories: Commercial Products, Anthrax Medical Countermeasures (MCM), Smallpox MCM, and Emergent Bioservices (CDMO). The Commercial Product segment focuses on the U.S. and Canadian markets, primarily offering naloxone products. NARCAN® Nasal Spray is available over-the-counter at retail pharmacies and digital commerce platforms, as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, law enforcement agencies, community organizations, substance abuse centers, and federal agencies. KLOXXADO® Nasal Spray is a prescription product sold at pharmacies and to public and government entities via physician-directed or standing order prescriptions. In 2023, the Company sold its travel health business—including rights to Vivotif®, Vaxchora®, the chikungunya vaccine candidate CHIKV VLP, and certain manufacturing and development facilities—to Bavarian Nordic. The Company has received $80.0 million in milestone payments from Bavarian Nordic and may receive up to $30.0 million in earn-out payments based on net sales of Vaxchora® and Vivotif®.
Emergent BioSolutions Secures $29 Million in Medical Countermeasure Orders: A Strategic Boost Amid Global Health Preparedness In an era where the capacities for rapid response to biological threats have become paramount, Emergent BioSolutions Inc. (NYSE: EBS), a prominent player in the bio-pharmaceutical sector, has recently solidified its position within the global medical countermeasures landscape. On September 19, 2025, the Maryland-based company announced that it has received new purchase orders valued at $29 million from an international government partner for a multi-product supply agreement focused on medical countermeasures (MCM). This agreement underscores a critical trend: governments worldwide are...
In a significant move aimed at bolstering public health accessibility, Emergent BioSolutions Inc. (NYSE: EBS) has announced the opening of a new distribution center specifically dedicated to its NARCAN® Nasal Spray product in Nevada. This strategic addition is part of the company s ongoing commitment to expanding the distribution capabilities of NARCAN, a vital medication that plays a critical role in reversing opioid overdoses. A National Solution to Opioid OverdosesWith the ongoing opioid crisis escalating, the demand for naloxone the active ingredient in NARCAN has surged. Opioid overdose remains a leading cause of death in various demographics across the United States, which underscores the importance o...
: Emergent BioSolutions Inc. is embarking on a strategic transition by divesting key assets, including its Reactive Skin Decontamination Lotion (RSDL) kit and its Baltimore-Camden manufacturing facility. This article highlights the recent acquisition agreements and their implications for both Emergent BioSolutions and the acquiring companies SERB Pharmaceuticals and Bora Pharmaceuticals. We also discuss the broader context of these transactions within the pharmaceutical industry, including the potential benefits and strategic shifts these companies may experience. The pharmaceutical landscape is constantly evolving, and companies often find it necessary to recalibrate their business strategies to enhance op...
Emergent BioSolutions Inc. has recently unveiled a new opioid emergency awareness public education campaign aimed at equipping people nationwide with the necessary knowledge to save lives using the Lay, Spray, Stay method. This campaign, sponsored by Emergent in collaboration with SAFE Project, features Pro Football Hall of Famer Emmitt Smith in a series of videos and radio segments. It aligns with Emergent s Ready to Rescue initiative, which seeks to debunk the stigma surrounding accidental opioid poisonings and educate Americans about the availability and use of NARCAN Nasal Spray for life-saving purposes.Ongoing Efforts to Combat the Opioid Epidemic:Emergent BioSolutions has long been at the forefront of ...
GAITHERSBURG, Md., June 20, 2024 Emergent BioSolutions Inc. (NYSE: EBS), a global biopharmaceutical company, has announced the sale of its Baltimore-Camden manufacturing site to an affiliate of Bora Pharmaceuticals Co., Ltd. (Bora, TWSE: 6472), for a total value of approximately $30 million. This strategic divestiture is part of Emergent s ongoing efforts to streamline its operations and focus on its core competencies in product and service offerings.The Baltimore-Camden site, a crucial segment of Emergent’s Contract Development and Manufacturing Organization (CDMO), specializes in clinical and commercial non-viral aseptic fill/finish services. The facility boasts four fill lines and provides extensive ...
Gaithersburg, Md., June 6, 2024In recognition of National Naloxone Awareness Day, Emergent BioSolutions Inc. (NYSE: EBS) is taking significant strides to address the opioid epidemic in the United States. As part of their ongoing commitment, the company has released topline results from a new survey aimed at assessing general population awareness on the dangers of opioid-related accidental overdoses and the protective role of naloxone, especially in cases involving fentanyl.The survey results have revealed a promising high level of awareness that fentanyl, a powerful synthetic opioid, is indeed an opioid and that naloxone can reverse overdoses caused by it. However, despite this encouraging awareness, gaps r...
Embracing Multi-Sectoral Action to Combat the Ongoing Opioid CrisisThe opioid crisis in the United States continues to escalate, with devastating consequences for public health and safety. Emergency BioSolutions Inc. (EBS), a leading pharmaceutical company, is dedicated to combating this crisis by expanding access to and awareness of NARCAN Nasal Spray, a life-saving intervention for opioid overdose emergencies.According to the U.S. Centers for Disease Control and Prevention (CDC), the number of overdose deaths reached a staggering 107,000 in 2022. This figure has steadily risen over the years, setting new annual records. A significant driver of this trend is the surge in synthetic opioid overdoses, particu...
Emergent Biosolutions Inc’s Comment on Sales, Marketing and Customers
The Company operates in markets addressing global public health threats such as smallpox, mpox, anthrax, Ebola, and opioid overdose emergencies. Its business is organized into four product and service categories: Commercial Products, Anthrax Medical Countermeasures (MCM), Smallpox MCM, and Emergent Bioservices (CDMO). The Commercial Product segment focuses on the U.S. and Canadian markets, primarily offering naloxone products. NARCAN® Nasal Spray is available over-the-counter at retail pharmacies and digital commerce platforms, as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, law enforcement agencies, community organizations, substance abuse centers, and federal agencies. KLOXXADO® Nasal Spray is a prescription product sold at pharmacies and to public and government entities via physician-directed or standing order prescriptions. In 2023, the Company sold its travel health business—including rights to Vivotif®, Vaxchora®, the chikungunya vaccine candidate CHIKV VLP, and certain manufacturing and development facilities—to Bavarian Nordic. The Company has received $80.0 million in milestone payments from Bavarian Nordic and may receive up to $30.0 million in earn-out payments based on net sales of Vaxchora® and Vivotif®.
Sources:
Emergent Biosolutions Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Emergent Biosolutions Inc’s corporate clients.
For your research, we’ve provided 9 tables on Emergent Biosolutions Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
160.69 %